Feb 01, 2021 6:30am EST Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates
Jan 25, 2021 6:30am EST Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080
Dec 17, 2020 6:30am EST Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update
Nov 30, 2020 8:30am EST Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010
Aug 25, 2020 7:30am EDT Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants
Aug 14, 2020 7:30am EDT Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update
Aug 04, 2020 7:35am EDT Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million
Aug 04, 2020 7:30am EDT Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics
Jul 20, 2020 7:30am EDT Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12
